Abstract
Marginal zone (MZ) B cells play an important role in the clearance of blood-borne bacterial infections via rapid T-independent IgM responses. We have previously demonstrated that MZ B cells respond rapidly and robustly to bacterial particulates. To determine the MZ-specific genes that are expressed to allow for this response, MZ and follicular (FO) B cells were sort purified and analyzed via DNA microarray analysis. We identified 181 genes that were significantly different between the two B cell populations. Ninety-nine genes were more highly expressed in MZ B cells while 82 genes were more highly expressed in FO B cells. To further understand the molecular mechanisms by which MZ B cells respond so rapidly to bacterial challenge, Id-positive and -negative MZ B cells were sort purified before (0 h) or after (1 h) i.v. immunization with heat-killed Streptococcus pneumoniae, R36A, and analyzed via DNA microarray analysis. We identified genes specifically up-regulated or down-regulated at 1 h following immunization in the Id-positive MZ B cells. These results give insight into the gene expression pattern in resting MZ vs FO B cells and the specific regulation of gene expression in Ag-specific MZ B cells following interaction with Ag.
Mature B lymphocytes play an integral role in the adaptive immune response via Ag presentation and Ab secretion. The mature splenic B cell population is divided into the marginal zone (MZ)7 and follicular (FO) B cell subsets based on anatomical location, cellular surface molecules, and functional immune responses (reviewed in Ref. 1). MZ B cells respond primarily to T-independent Ags and are proposed to bridge the gap between the rapid Ag nonspecific response and the delayed Ag-specific response. FO B cells respond primarily to T-dependent Ags and are responsible for the generation of long-term memory. However, the exact molecular mechanism by which each subset of B cells function is not fully understood.
MZ B cells are primarily nonrecirculating, located at the outer limit of the white pulp region, and characterized by the expression of IgMhighIgDlowCD1d+CD21highCD23low. The MZ B cell repertoire is enriched with B cells expressing germline-encoded BCRs (2, 3, 4), some of which have a low level of self-reactivity. Following activation, MZ B cells increase B7-1 and B7-2 expression, develop into plasmablasts more readily, and are more sensitive to LPS stimulation than their FO counterparts (5, 6). In addition to rapid production of IgM Ab, MZ B cells also possess the ability to capture and shuttle Ag to follicular dendritic cells (7) as well as to efficiently activate naive T cells directly (8), suggesting a potential role for MZ B cells in T cell-dependent Ab responses also. In addition to anatomical location and cellular functions, MZ and FO B cells differentially express a number of cell surface molecules. We have previously shown that CD9, a member of the tetraspanin family, is expressed by the MZ and B1 B cell populations but not by FO B cells (9). Additionally, we identified Fc receptor homologue 3 (FcRH3) as a potentially immunoregulatory molecule expressed by MZ and B1 cells, but not by FO B cells (10). Recently, the scavenger receptor CD36 was identified as a marker predominantly expressed by MZ B cells (11). Taken together, it is clear that MZ B cells fill a specific niche in the splenic environment through unique expression and regulation of specific genes.
The development of DNA microarray technology has allowed for the rapid analysis of genome-wide gene expression profiles. Using this technology, we set out to identify differentially regulated genes between FO and MZ B cells as well as the genes specifically up-regulated or down-regulated following activation. DNA microarray analysis of FACS-sorted resting MZ and FO B cells from MD4 mice revealed 181 genes that are differentially expressed in the resting B cell populations. Ninety-nine genes were more highly expressed in MZ B cells while 82 genes were more highly expressed in FO B cells. In addition, a comparative DNA microarray analysis of FACS-sorted MZ Id-positive and -negative B cells at 0 and 1 h following i.v. immunization with heat-killed Streptococcus pneumoniae, R36A, revealed genes specifically up-regulated or down-regulated following activation. These results give new insight into the differences between MZ and FO B cells and reveal new candidate genes and pathways to study.
Materials and Methods
Animals
SWR/J and C3H/HeJ samples were kindly provided by T. Waldschmidt (University of Iowa, Iowa City, IA) and were from mice housed at the University of Iowa in specific pathogen-free conditions. MD4 anti-HEL conventional transgenic (Tg) mice were originally obtained from Dr. C. Goodnow (Australian National University, Canberra, Australia) (12). MD4 transgenic mice are on a C57BL/6 (B6) background. M167 Tg mice have been described previously (13). The IL-10/Thy1.1 reporter mice were generously provided by C. Weaver (University of Alabama at Birmingham, Birmingham, AL) as described previously (14). IL-10/Thy1.1 mice were crossed with M167 Tg mice. All mice were bred and housed within the pathogen-free facility at the University of Alabama at Birmingham and used at 6–8 wk of age according to approved animal protocols.
DNA microarray analysis
Microarray analysis was performed as described previously (15). Briefly, total RNA was isolated from sort-purified cell populations using an RNeasy Mini kit with on-column Dnase digestion (Qiagen) and, in accordance with expression analysis technical instructions from Affymetrix, cDNA was synthesized. cRNA was synthesized with BioArray high-yield transcript labeling kit (Enzo). Labeled cRNA (∼15 μg) was chemically fragmented for 35 min. at 94°C. Affymetrix MG U74Av2 oligonucleotide GeneChips (Affymetrix) were probed, hybridized, stained, washed, and scanned according to the manufacturer’s protocol at the University of Minnesota Biomedical Genomics Center facility (Minneapolis, MN). Each sort-purified cell population was processed independently as true biological replicates.
Flow cytometry and cell sorting
FACS analysis was performed as described previously (16). Briefly, total splenocytes were collected, RBCs were lysed with ammonium chloride, and the splenocytes were stained with different combinations of the following Abs: fluorescein (FITC)-, PE-, or allophycocyanin-conjugated anti-mouse CD21, CD23, Thy1.1, CD19 (eBioscience), goat anti-human regulator of G protein signaling (RGS) 10 (RGS10; Santa Cruz Biotechnology), goat anti-mouse D6 β-chemokine receptor, and rabbit anti-human Sharp2/Stra13 (Abcam). All anti-human Abs cross-react with mouse targets. For intracellular FACS analysis, cells were then washed, fixed, and permeabilized using the Cytofix/Cytoperm (BD Biosciences) kit according to manufacturer’s directions. All samples were analyzed using a FACSCalibur flow cytometer or FACSAria cell sorter (BD Biosciences). The data were analyzed using FlowJo software (Tree Star, Inc.).
Western blot analysis
Western blot analysis was performed as described previously (17). Briefly, following B cell isolation the cells were lysed, total protein was quantitated using a protein quantitation assay (Bio-Rad), and then protein samples (5–20 μg) were resolved by electrophoresis on 10% polyacrylamide gels (Bio-Rad), transferred to Immobilon-P polyvinylidene difluoride membranes (Millipore), probed with goat anti-human RGS10, anti-actin (Santa Cruz Biotechnology), or goat anti-mouse D6 β-chemokine receptor (Abcam), detected with HRP-labeled anti-mouse, goat, and rabbit Abs (Santa Cruz Biotechnology), and developed with the LumiGLO detection kit (Cell Signaling).
RNA isolation and PCR
Total RNA was isolated from ∼5 × 105 sort-purified MZ B cells using TRIzol reagent (Invitrogen) following the manufacturer’s directions. RT-PCR was performed using the Omniscript RT kit (Qiagen) following the manufacturer’s directions. The following gene-specific primers were used to amplify the cDNA obtained from the RT kit using Fisher Taq and PCR products were resolved using a 1% agarose gel and visualized using ethidium bromide. Primers used were as follows: β-actin, 5′-TACAGCTTCACCACCACAGC-3′ (forward) and 5′-AAGGAAGGCTGGAAAAGAGC-3′ (reverse); D6, 5′-CTTCCAGCTGAACCTTCTGG-3′ (forward) and 5′-CGAGTGCAGAAACAAGGTGA-3′ (reverse); RGS10, 5′-GCCTTAAGAGCACAGCCAAG-3′ (forward) and 5′-CTTTTCCTGCATCTGCTTCC-3′ (reverse); Thy1.1, 5′-ACCAAAACCTTCGCCTGGACTG-3′ (forward) and 5′-TCCTTGGGGTCTTCTACCTTTCTC-3′ (reverse); IL-10, 5′-CATGGGTCTTGGGAAGAGAA-3′ (forward) and 5′-CATTCCCAGAGGAATTGCAT-3′ (reverse); Stra13, 5′-GGATTTGCCCACATGTACC-3′ (forward) and 5′-TCAATGCTTTCACGTGCTTC-3′ (reverse). The annealing temperature for all primers was 60°C.
Data processing
Expressionist Pro 1.0 (GeneData) was used to generate relative expression values for each transcript using the MAS 5.0 algorithm, default settings, and a scaling factor of 1500 to control for minor cross-chip differences in hybridization intensities. GeneData Expressionist and Microsoft Excel were used for statistical analysis. Hierarchical clustering analysis was performed using Cluster and visualized in TreeView, as described previously (18).
Statistics
Data with three or more groups were analyzed by a one-way ANOVA and statistical significance was determined by p < 0.05. Data with two groups were analyzed by a two-tailed paired t test and statistical significance was determined by a p < 0.02.
Results
DNA microarray analysis of resting MZ and FO B cells
The mature splenic B cell population is divided into MZ and FO B cells based on anatomical location, cellular surface molecule expression, and functional immune responses (reviewed in Ref. 1). DNA microarray analysis was used to determine differences in gene expression profiles between MZ and FO B cell populations. Splenocytes from B6 MD4 Tg mice were sort purified to obtain paired MZ (B220+CD21highCD23low) and FO (B220+CD21intCD23+, where “int” is “intermediate”) B cell samples. Postsort analysis revealed >95% purity of each B cell population (data not shown). MD4 mice carry a heavy and a light chain transgene specific for hen egg lysozyme Ag (12) and were used because >90% of their B cells express the transgenic BCR, thereby potentially reducing the variability due to a polyclonal repertoire. Gene expression was assessed in three replicates of each B cell population the using Affymetrix U74A mouse GeneChip microarray representing ∼11,000 transcripts. Expression levels were quantified using GeneData Expressionist Pro 1.0 software and the data from each array were analyzed to identify the genes that were differentially expressed between the MZ and FO B cell populations. Differential expression was defined as a mean fold change of >2 and p < 0.02 by Student’s t test.
Based on this definition, we identified 181 transcripts differentially expressed between the two populations. Ninety-nine transcripts (∼55% of total) were more highly expressed in MZ B cells relative to FO B cells, whereas 82 transcripts (∼45% of total) were more highly expressed in FO B cells relative to MZ B cells. To better visualize the data, each expression value was divided by the mean expression of all six samples of that transcript and converted into log2 space. The data were then analyzed by unsupervised hierarchical clustering as described previously (18). The data showed tight clustering of the three replicates of each cell type with a coefficient of correlation between any two replicate samples >0.98. The 181 gene transcripts identified were grouped into the following broad functional classifications: motility/adhesion (Fig. 1,A), immune response (Fig. 1,B), apoptosis (Fig. 1,C), proliferation (Fig. 1,D), transcription factors (Fig. 2,A), signal transduction (Fig. 2,B), metabolism (data not shown), or miscellaneous (data not shown). All 181 genes are listed in Table I.
Expression profile of differentially expressed genes between FO and MZ B cells. DNA microarray analysis identified 181 genes that were significantly different in sort-purified FO vs MZ B cells from MD4 transgenic mice (B6 background). The identified transcripts have a fold change of >2 and p < 0.02 by t test. The differentially expressed genes were grouped into various functional categories as follows: motility/adhesion (A), immune response (B), apoptosis (C), and proliferation (D). Shown are normalized expression values greater than (yellow), near (black), or less than (blue) the mean of that gene. Each column represents one independent sample of sort-purified FO or MZ B cells. Genes or transcripts are represented in rows. Clustering of the genes was unsupervised.
Expression profile of differentially expressed genes between FO and MZ B cells. DNA microarray analysis identified 181 genes that were significantly different in sort-purified FO vs MZ B cells from MD4 transgenic mice (B6 background). The identified transcripts have a fold change of >2 and p < 0.02 by t test. The differentially expressed genes were grouped into various functional categories as follows: motility/adhesion (A), immune response (B), apoptosis (C), and proliferation (D). Shown are normalized expression values greater than (yellow), near (black), or less than (blue) the mean of that gene. Each column represents one independent sample of sort-purified FO or MZ B cells. Genes or transcripts are represented in rows. Clustering of the genes was unsupervised.
Expression profile of differentially expressed genes between FO and MZ B cells. DNA microarray analysis identified 181 genes that were significantly different in sort-purified FO vs MZ B cells from MD4 Tg mice (B6 background). The identified transcripts have a fold change of >2 and p < 0.02 by t test. The differentially expressed genes were grouped into various functional categories as follows: transcription factors (A) and signal transduction (B). Shown are normalized expression values greater than (yellow), near (black), or less than (blue) the mean of that gene. Each column represents one independent sample of sorted FO or MZ B cells. Genes or transcripts are represented in rows. Clustering of the genes was unsupervised.
Expression profile of differentially expressed genes between FO and MZ B cells. DNA microarray analysis identified 181 genes that were significantly different in sort-purified FO vs MZ B cells from MD4 Tg mice (B6 background). The identified transcripts have a fold change of >2 and p < 0.02 by t test. The differentially expressed genes were grouped into various functional categories as follows: transcription factors (A) and signal transduction (B). Shown are normalized expression values greater than (yellow), near (black), or less than (blue) the mean of that gene. Each column represents one independent sample of sorted FO or MZ B cells. Genes or transcripts are represented in rows. Clustering of the genes was unsupervised.
Identification of strain-specific differences in gene expression between resting FO and MZ B cells.
To determine whether any strain-specific differences exist between MZ and FO B cell gene expression profiles, we expanded our gene expression analysis to include two additional mouse strains, C3H/HeJ (C3H) and SWR/J (SWR). C3H mice have an enlarged MZ B cell population relative to B6 mice while SWR mice have a smaller MZ B cell population relative to B6 mice (data not shown). The 181 transcripts found to be significantly different between FO and MZ B cells were analyzed for their expression levels in C3H and SWR mice, respectively. Although the absolute signal intensities varied across strains (Table I), the fold changes between MZ and FO B cell gene expression were comparable (Fig. 3,A). We identified 29 genes (∼16% of total) that appeared to have different expression profiles between FO and MZ B cells in the C3H and SWR strains relative to the B6 strain (Fig. 3,B and Table II). These strain-specific differences might reflect changes in genes regulating MZ B cell size, strain-specific functional differences, or polymorphisms that influence probe hybridization but have no functional consequences.
Identification of strain-specific differences in gene expression profiles between FO and MZ B cells. Gene expression profile of splenic FO and MZ B cells from B6, SWR, and C3H mice. The profile includes 181 gene transcripts with a fold change of >2 and p < 0.02 by t test. A, Hierarchical analysis of 152 genes with consistent regulation across the three mouse strains. B, Hierarchical analysis of 29 genes with strain-specific differences in MZ vs FO gene expression profiles. Shown are normalized expression values greater than (yellow), near (black), or less than (blue) the mean of that strain. Each column represents one sample of sorted FO or MZ B cells. Genes or transcripts are represented in rows. Clustering of genes was unsupervised.
Identification of strain-specific differences in gene expression profiles between FO and MZ B cells. Gene expression profile of splenic FO and MZ B cells from B6, SWR, and C3H mice. The profile includes 181 gene transcripts with a fold change of >2 and p < 0.02 by t test. A, Hierarchical analysis of 152 genes with consistent regulation across the three mouse strains. B, Hierarchical analysis of 29 genes with strain-specific differences in MZ vs FO gene expression profiles. Shown are normalized expression values greater than (yellow), near (black), or less than (blue) the mean of that strain. Each column represents one sample of sorted FO or MZ B cells. Genes or transcripts are represented in rows. Clustering of genes was unsupervised.
Genes differentially expressed between FO and MZ B cells from B6, SWR, and C3H strains of mice
Affymetrix Identifier . | Gene Symbol . | Gene Title . | Relative Expression . | . | . | Relative Expression . | . | . | Relative Expression . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | B6 FO . | B6 MZ . | Fold Difference (MZ/FO) . | SWR FO . | SWR MZ . | Fold Difference (MZ/FO) . | C3H FO . | C3H MZ . | Fold Difference (MZ/FO) . | ||||||
93195_at | Mfhas1 | Malignant fibrous histiocytoma-amplified sequence | 1143 | 5462 | 4.8 | 2857 | 2424 | 0.85 | 3446 | 3592 | 1.04 | ||||||
160069_at | Gmnn | Geminin | 422 | 1174 | 2.8 | 376 | 323 | 0.86 | 229 | 445 | 1.94 | ||||||
93833_s_at | Hist1h2bc | Histone 1, H2bc | 773 | 2093 | 2.7 | 617 | 697 | 1.13 | 1189 | 536 | 0.45 | ||||||
161788_f_at | S1P1 | Sphingolipid G protein-coupled receptor 1 | 565 | 1476 | 2.6 | 1332 | 747 | 0.56 | 936 | 562 | 0.60 | ||||||
94995_at | RIKEN cDNA A030007L17 gene | 848 | 2186 | 2.6 | 926 | 734 | 0.79 | 1184 | 817 | 0.69 | |||||||
92925_at | Cebpb | CCAAT/enhancer binding protein (C/EBP), β | 1911 | 4882 | 2.6 | 12638 | 12321 | 0.97 | 20455 | 13386 | 0.65 | ||||||
100516_at | Chka | Choline kinase α | 874 | 2195 | 2.5 | 1728 | 1646 | 0.95 | 880 | 728 | 0.83 | ||||||
160841_at | Dbp | D site albumin promoter binding protein | 239 | 540 | 2.3 | 226 | 129 | 0.57 | 293 | 336 | 1.15 | ||||||
102104_f_at | Est | 2147 | 4844 | 2.3 | 1411 | 2614 | 1.85 | 1284 | 1133 | 0.88 | |||||||
99024_at | Mxd4 | Max dimerization protein 4 | 5977 | 12958 | 2.2 | 6053 | 6769 | 1.12 | 6873 | 6672 | 0.97 | ||||||
95387_f_at | Sema4b | Semaphorin 4B | 8465 | 17775 | 2.1 | 4483 | 3837 | 0.86 | 4046 | 4411 | 1.09 | ||||||
103460_at | Ddit4 | DNA damage-inducible transcript 4 | 3274 | 6711 | 2.0 | 1631 | 1280 | 0.78 | 1275 | 3062 | 2.40 | ||||||
100573_f_at | Gpi1 | Glucose phosphate isomerase 1 | 1410 | 2889 | 2.0 | 3126 | 1986 | 0.64 | 1911 | 2109 | 1.10 | ||||||
98868_at | Bcl2 | B cell leukemia/lymphoma 2 | 1203 | 2437 | 2.0 | 1411 | 1261 | 0.89 | 1030 | 833 | 0.81 | ||||||
94431_at | St6gal1 | β-Galactoside α-2,6-ialyltransferase 1 | 1562 | 331 | 4.7 | 922 | 410 | 2.25 | 850 | 872 | 0.98 | ||||||
103504_at | Ssbp2 | Single-stranded DNA binding protein 2 | 1538 | 335 | 4.6 | 85 | 224 | 0.38 | 496 | 182 | 2.72 | ||||||
98918_at | Txndc5 | Thioredoxin domain containing 5 | 5318 | 1447 | 3.7 | 745 | 893 | 0.83 | 3928 | 1955 | 2.01 | ||||||
104523_at | Lrrc8c | Leucine rich repeat containing 8 family, member C | 1533 | 483 | 3.2 | 905 | 1098 | 0.82 | 970 | 693 | 1.40 | ||||||
97890_at | Sgk | Serum/glucocorticoid regulated kinase | 1107 | 351 | 3.2 | 1857 | 1923 | 0.97 | 1674 | 717 | 2.33 | ||||||
93193_at | Adrb2 | Adrenergic receptor, β2 | 5831 | 1961 | 3.0 | 8025 | 9318 | 0.86 | 3784 | 5394 | 0.70 | ||||||
98083_at | Klf6 | Krüppel-like factor 6 | 4002 | 1522 | 2.6 | 14189 | 19034 | 0.75 | 18319 | 14977 | 1.22 | ||||||
99622_at | Klf4 | Krüppel-like factor 4 | 697 | 278 | 2.5 | 10472 | 25698 | 0.41 | 18855 | 23655 | 0.80 | ||||||
102892_at | Kcnab2 | Potassium voltage-gated channel | 2707 | 1133 | 2.4 | 2525 | 2350 | 1.07 | 1751 | 1970 | 0.89 | ||||||
100554_at | Pdlim1 | PDZ and LIM domain 1 (elfin) | 2352 | 1009 | 2.3 | 443 | 336 | 1.32 | 147 | 243 | 0.61 | ||||||
97203_at | Marcksl1 | MARCKS-like 1 | 2027 | 900 | 2.3 | 5719 | 7047 | 0.81 | 5684 | 6025 | 0.94 | ||||||
94753_at | Gna15 | Guanine nucleotide binding protein, α15 | 689 | 315 | 2.2 | 51 | 136 | 0.37 | 84 | 136 | 0.61 | ||||||
98335_at | Rece1 | Replication factor C1 | 2339 | 1104 | 2.1 | 1421 | 1647 | 0.86 | 1758 | 1339 | 1.31 | ||||||
101502_at | Tgif | TG interacting factor | 2690 | 1292 | 2.1 | 27576 | 36312 | 0.76 | 23520 | 24132 | 0.97 | ||||||
100576_at | Pafah1b3 | Platelet-activating factor acetylhydrolase | 3106 | 1545 | 2.0 | 1069 | 1280 | 0.84 | 1627 | 988 | 1.65 |
Affymetrix Identifier . | Gene Symbol . | Gene Title . | Relative Expression . | . | . | Relative Expression . | . | . | Relative Expression . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | B6 FO . | B6 MZ . | Fold Difference (MZ/FO) . | SWR FO . | SWR MZ . | Fold Difference (MZ/FO) . | C3H FO . | C3H MZ . | Fold Difference (MZ/FO) . | ||||||
93195_at | Mfhas1 | Malignant fibrous histiocytoma-amplified sequence | 1143 | 5462 | 4.8 | 2857 | 2424 | 0.85 | 3446 | 3592 | 1.04 | ||||||
160069_at | Gmnn | Geminin | 422 | 1174 | 2.8 | 376 | 323 | 0.86 | 229 | 445 | 1.94 | ||||||
93833_s_at | Hist1h2bc | Histone 1, H2bc | 773 | 2093 | 2.7 | 617 | 697 | 1.13 | 1189 | 536 | 0.45 | ||||||
161788_f_at | S1P1 | Sphingolipid G protein-coupled receptor 1 | 565 | 1476 | 2.6 | 1332 | 747 | 0.56 | 936 | 562 | 0.60 | ||||||
94995_at | RIKEN cDNA A030007L17 gene | 848 | 2186 | 2.6 | 926 | 734 | 0.79 | 1184 | 817 | 0.69 | |||||||
92925_at | Cebpb | CCAAT/enhancer binding protein (C/EBP), β | 1911 | 4882 | 2.6 | 12638 | 12321 | 0.97 | 20455 | 13386 | 0.65 | ||||||
100516_at | Chka | Choline kinase α | 874 | 2195 | 2.5 | 1728 | 1646 | 0.95 | 880 | 728 | 0.83 | ||||||
160841_at | Dbp | D site albumin promoter binding protein | 239 | 540 | 2.3 | 226 | 129 | 0.57 | 293 | 336 | 1.15 | ||||||
102104_f_at | Est | 2147 | 4844 | 2.3 | 1411 | 2614 | 1.85 | 1284 | 1133 | 0.88 | |||||||
99024_at | Mxd4 | Max dimerization protein 4 | 5977 | 12958 | 2.2 | 6053 | 6769 | 1.12 | 6873 | 6672 | 0.97 | ||||||
95387_f_at | Sema4b | Semaphorin 4B | 8465 | 17775 | 2.1 | 4483 | 3837 | 0.86 | 4046 | 4411 | 1.09 | ||||||
103460_at | Ddit4 | DNA damage-inducible transcript 4 | 3274 | 6711 | 2.0 | 1631 | 1280 | 0.78 | 1275 | 3062 | 2.40 | ||||||
100573_f_at | Gpi1 | Glucose phosphate isomerase 1 | 1410 | 2889 | 2.0 | 3126 | 1986 | 0.64 | 1911 | 2109 | 1.10 | ||||||
98868_at | Bcl2 | B cell leukemia/lymphoma 2 | 1203 | 2437 | 2.0 | 1411 | 1261 | 0.89 | 1030 | 833 | 0.81 | ||||||
94431_at | St6gal1 | β-Galactoside α-2,6-ialyltransferase 1 | 1562 | 331 | 4.7 | 922 | 410 | 2.25 | 850 | 872 | 0.98 | ||||||
103504_at | Ssbp2 | Single-stranded DNA binding protein 2 | 1538 | 335 | 4.6 | 85 | 224 | 0.38 | 496 | 182 | 2.72 | ||||||
98918_at | Txndc5 | Thioredoxin domain containing 5 | 5318 | 1447 | 3.7 | 745 | 893 | 0.83 | 3928 | 1955 | 2.01 | ||||||
104523_at | Lrrc8c | Leucine rich repeat containing 8 family, member C | 1533 | 483 | 3.2 | 905 | 1098 | 0.82 | 970 | 693 | 1.40 | ||||||
97890_at | Sgk | Serum/glucocorticoid regulated kinase | 1107 | 351 | 3.2 | 1857 | 1923 | 0.97 | 1674 | 717 | 2.33 | ||||||
93193_at | Adrb2 | Adrenergic receptor, β2 | 5831 | 1961 | 3.0 | 8025 | 9318 | 0.86 | 3784 | 5394 | 0.70 | ||||||
98083_at | Klf6 | Krüppel-like factor 6 | 4002 | 1522 | 2.6 | 14189 | 19034 | 0.75 | 18319 | 14977 | 1.22 | ||||||
99622_at | Klf4 | Krüppel-like factor 4 | 697 | 278 | 2.5 | 10472 | 25698 | 0.41 | 18855 | 23655 | 0.80 | ||||||
102892_at | Kcnab2 | Potassium voltage-gated channel | 2707 | 1133 | 2.4 | 2525 | 2350 | 1.07 | 1751 | 1970 | 0.89 | ||||||
100554_at | Pdlim1 | PDZ and LIM domain 1 (elfin) | 2352 | 1009 | 2.3 | 443 | 336 | 1.32 | 147 | 243 | 0.61 | ||||||
97203_at | Marcksl1 | MARCKS-like 1 | 2027 | 900 | 2.3 | 5719 | 7047 | 0.81 | 5684 | 6025 | 0.94 | ||||||
94753_at | Gna15 | Guanine nucleotide binding protein, α15 | 689 | 315 | 2.2 | 51 | 136 | 0.37 | 84 | 136 | 0.61 | ||||||
98335_at | Rece1 | Replication factor C1 | 2339 | 1104 | 2.1 | 1421 | 1647 | 0.86 | 1758 | 1339 | 1.31 | ||||||
101502_at | Tgif | TG interacting factor | 2690 | 1292 | 2.1 | 27576 | 36312 | 0.76 | 23520 | 24132 | 0.97 | ||||||
100576_at | Pafah1b3 | Platelet-activating factor acetylhydrolase | 3106 | 1545 | 2.0 | 1069 | 1280 | 0.84 | 1627 | 988 | 1.65 |
D6 β-chemokine receptor and RGS10 are more highly expressed in MZ than in FO B cells
MZ B cells provide a rapid response to blood-borne bacterial particulates, in part because of their localization in the spleen. For example, blood-borne Ags accumulate within the splenic MZ as early as 30 min following i.v. immunization (8), giving an opportunity for MZ B cells to sample blood and respond rapidly to an Ag. A number of factors have been shown to play a role in MZ B cell localization within the splenic microenvironment including sphingosine-1-phosphate receptor type 1 (S1P1) (19) and the presence of MZ macrophages (20) and integrins (21). In addition, in vivo injection of pertussis toxin disrupts MZ localization, suggesting the involvement of G protein-coupled receptor(s) (22). The current microarray data identified a number of molecules that are potentially involved in the migration, localization, and/or retention of MZ B cells in the splenic MZ. Two proteins more highly expressed in MZ B cells relative to FO B cells were the D6 β-chemokine receptor and the RGS10 regulator of G protein signaling protein. To confirm that these two proteins are indeed more highly expressed in MZ B cells, resting splenic MZ and FO B cells were sort purified and analyzed for the level of D6 and RGS10 mRNA (Fig. 4,A) and protein (Fig. 4, B–D) by RT-PCR, Western blotting, and FACS, respectively. Thus, resting MZ B cells express D6 and RGS10 at higher levels than FO B cells with the potential to be involved in MZ B cell localization.
MZ B cells express higher levels of D6 and RGS10 relative to FO B cells. Resting splenic MZ and FO B cells were sort purified and total RNA and protein were isolated. Resting MZ B cells express higher mRNA (A) and protein (B) levels of D6 and RGS10 as determined by RT-PCR and Western blotting, respectively. Total splenocytes were isolated and analyzed via FLOW cytometry. The expression levels of D6 isotype (0.3%), MZ B cell (88.8%), and FO B cell (11.8%) (C) and RGS10 isotype (0.2%), MZ B cell (82.1%), and FO B cell (1.1%) (D) are displayed as histogram plots.
MZ B cells express higher levels of D6 and RGS10 relative to FO B cells. Resting splenic MZ and FO B cells were sort purified and total RNA and protein were isolated. Resting MZ B cells express higher mRNA (A) and protein (B) levels of D6 and RGS10 as determined by RT-PCR and Western blotting, respectively. Total splenocytes were isolated and analyzed via FLOW cytometry. The expression levels of D6 isotype (0.3%), MZ B cell (88.8%), and FO B cell (11.8%) (C) and RGS10 isotype (0.2%), MZ B cell (82.1%), and FO B cell (1.1%) (D) are displayed as histogram plots.
Gene expression profile of MZ Id+ B cells before and after stimulation
In addition to the differential phenotypes of resting FO and MZ B cells, MZ B cells respond very differently to Ag than FO B cells. Following activation with Ag, MZ B cells increase B7-1 and B7-2 expression, develop into plasmablasts more readily, and are more sensitive to LPS stimulation than their FO counterparts (5, 6). Along with the rapid production of IgM Ab, MZ B cells also possess the ability to efficiently activate naive T cells (8). However, the genes that are rapidly up-regulated and down-regulated in MZ B cells following activation with Ag have not been fully characterized. To determine the gene expression profile of Ag (Id)-positive MZ B cells before and after activation, M167 Tg mice were immunized i.v. with heat-killed S. pneumoniae, R36A, and Id+ and Id− MZ B cells were sort purified at 0 and 1 h following immunization. The samples were analyzed via DNA microarray analysis as described for the resting MZ vs FO B cell microarray above. The gene transcripts identified to significantly increase or decrease were grouped into the following broad functional classifications: chemokines (Fig. 5,A), chemokine receptors (Fig. 5,B), cytokines (Fig. 5,C), cytokine receptors (Fig. 5,B), apoptosis (Fig. 6,A), and immune cell markers (Fig. 6 B).
Regulated genes in Id+ MZ B cells after activation. MZ Id+ (Ag+) and Id− (Ag−) B cells were isolated from M167 Tg mice at 0 and 1 h after i.v. immunization with heat killed S. pneumoniae R36A. DNA microarray analysis identified genes that were significantly up-regulated and down-regulated in the Id+ MZ B cells 1 h after activation. The genes specifically regulated in the Id+ MZ B cells were grouped into various functional categories as follows: chemokines (A), chemokine receptors (B), cytokines (C), and cytokine receptors (D). Shown are normalized expression values greater than (yellow), near (black), or less than (blue) the mean of that gene. Each column represents one independent sample. Genes or transcripts are represented in rows. Clustering of the genes was unsupervised.
Regulated genes in Id+ MZ B cells after activation. MZ Id+ (Ag+) and Id− (Ag−) B cells were isolated from M167 Tg mice at 0 and 1 h after i.v. immunization with heat killed S. pneumoniae R36A. DNA microarray analysis identified genes that were significantly up-regulated and down-regulated in the Id+ MZ B cells 1 h after activation. The genes specifically regulated in the Id+ MZ B cells were grouped into various functional categories as follows: chemokines (A), chemokine receptors (B), cytokines (C), and cytokine receptors (D). Shown are normalized expression values greater than (yellow), near (black), or less than (blue) the mean of that gene. Each column represents one independent sample. Genes or transcripts are represented in rows. Clustering of the genes was unsupervised.
Regulated genes in Id+ MZ B cells after activation. MZ Id+ (Ag+) and Id− (Ag−) B cells were isolated from M167 Tg mice at 0 and 1 h after i.v. immunization with heat killed S. pneumoniae R36A. DNA microarray analysis identified genes that were significantly up-regulated and down-regulated in the Id+ MZ B cells 1 h after activation. The genes specifically regulated in the Id+ MZ B cells were grouped into various functional categories as follows: apoptosis (A) and immune cell markers (B). Shown are normalized expression values greater than (yellow), near (black), or less than (blue) the mean of that gene. Each column represents one independent sample. Genes or transcripts are represented in rows. Clustering of the genes was unsupervised.
Regulated genes in Id+ MZ B cells after activation. MZ Id+ (Ag+) and Id− (Ag−) B cells were isolated from M167 Tg mice at 0 and 1 h after i.v. immunization with heat killed S. pneumoniae R36A. DNA microarray analysis identified genes that were significantly up-regulated and down-regulated in the Id+ MZ B cells 1 h after activation. The genes specifically regulated in the Id+ MZ B cells were grouped into various functional categories as follows: apoptosis (A) and immune cell markers (B). Shown are normalized expression values greater than (yellow), near (black), or less than (blue) the mean of that gene. Each column represents one independent sample. Genes or transcripts are represented in rows. Clustering of the genes was unsupervised.
We focused on the Ag responsive Id+ MZ B cells and the genes that were regulated following i.v. immunization with R36A. The Id+ MZ B cell gene expression profile exhibited an activated phenotype at 1 h post-immunization, as would be predicted. The Id+ MZ B cells rapidly down-regulated proapoptotic genes such as multiple caspase proteins, annexin A4, and programmed cell death proteins while concurrently up-regulating anti-apoptotic genes such as Bcl-like proteins. MZ B cells also up-regulated a number of cytokine genes including IL-10, IL-6, TGF-β, and IL-1β while down-regulating many cytokine receptors. Chemokine ligands such as CXCL10, CXCL2, CCL3, CXCL5, and CCL4 were up-regulated while chemokine receptors were either up-regulated (CCR7) or down-regulated (D6, CCR5, and RDC-1). In addition, we cross-referenced the 99 transcripts that were more highly expressed in the MZ B cells relative to FO B cells with the expression profile in the Id+ MZ B cells 1 h after activation to determine whether any significant changes occurred (Table III). Six of the 99 genes (6%) more highly expressed in MZ B cells were up-regulated after activation in the MZ Id+ B cells while 17 of the 99 genes (17%) were down-regulated. Taken together, these results suggest that Id+ MZ B cells have a unique gene expression profile following i.v. immunization with R36A.
Genes more highly expressed in MZ B cells relative to FO B cells and specifically regulated in MZ Id+ B cells following activation
Affymetrix Identifier . | Gene Symbol . | Gene Title . | Relative Expression . | . | . | Relative Expression . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | B6 FO . | B6 MZ . | Fold Difference (MZ/FO) . | MZ Id+ (0 h) . | MZ Id+ (1 h) . | Fold Difference (1 h/0 h) . | ||||
95462_at | Bzw2 | Basic leucine zipper and W2 domains 2 | 1482 | 8442 | 5.7 | 3855 | 13947 | 3.6 | ||||
92217_s_at | Gp49 | Glycoprotein 49 A/B | 161 | 2762 | 17.2 | 2530 | 13563 | 5.4 | ||||
100325_at | Gp49 | Glycoprotein 49 A/B | 394 | 5124 | 13.0 | 2530 | 13563 | 5.4 | ||||
93013_at | Id2 | Inhibitor of DNA binding 2 | 2417 | 6577 | 2.7 | 9220 | 46793 | 5.1 | ||||
95661_at | CD9 | CD9 antigen | 480 | 2677 | 5.6 | 8265 | 16347 | 2.0 | ||||
104701_at | Bhlhb2 | Basic helix-loop-helix domain containing | 272 | 1490 | 5.5 | 6307 | 22934 | 3.6 | ||||
102914_s_at | Bcl2a1 | B cell leukemia/lymphoma 2 related protein A1 | 3284 | 10193 | 3.1 | 30696 | 152568 | 5.0 | ||||
161788_f_at | S1P1 | Sphingolipid G-protein-coupled receptor 1 | 565 | 1476 | 2.6 | 129 | 18 | 0.14 | ||||
97740_at | Dusp16 | Dual specificity phosphatase 16 | 787 | 4075 | 5.2 | 312 | 9 | 0.03 | ||||
93101_s_at | Nedd4 | Neural precursor cell expressed | 660 | 3176 | 4.8 | 3668 | 565 | 0.15 | ||||
99071_at | Mpeg1 | Macrophage expressed gene 1 | 2402 | 8938 | 3.7 | 55 | 13 | 0.24 | ||||
95758_at | Scd2 | Stearoyl-Coenzyme A desaturase 2 | 4483 | 12233 | 2.7 | 6858 | 821 | 0.12 | ||||
160711_at | Decr1 | 2,4-dienoyl CoA reductase 1, mitochondrial | 187 | 553 | 3.0 | 670 | 364 | 0.54 | ||||
160069_at | Gmnn | Geminin | 422 | 1174 | 2.8 | 905 | 216 | 0.24 | ||||
102410_at | Hs3st1 | Heparan sulfate (glucosamine) 3-O-sulfotransferase | 575 | 1392 | 2.4 | 2749 | 254 | 0.09 | ||||
97949_at | Fgl2 | Fibrinogen-like protein 2 | 314 | 752 | 2.4 | 570 | 242 | 0.42 | ||||
98417_at | Mx1 | myxovirus (influenza virus) resistance 1 | 260 | 608 | 2.3 | 428 | 233 | 0.54 | ||||
160841_at | Dbp | D site albumin promoter binding protein | 239 | 540 | 2.3 | 516 | 121 | 0.23 | ||||
95387_f_at | Sema4b | Semaphorin 4B | 8465 | 17775 | 2.1 | 1495 | 271 | 0.18 | ||||
98026_g_at | Evi2a | Ecotropic viral integration site 2a | 3528 | 7178 | 2.0 | 618 | 271 | 0.44 | ||||
93430_at | Cmkor1 | Chemokine orphan receptor 1 | 78 | 4369 | 56.0 | 8291 | 1092 | 0.13 | ||||
160495_at | Ahr | Aryl-hydrocarbon receptor | 31 | 249 | 8.0 | 735 | 404 | 0.55 | ||||
98309_at | Ccbp2 | Chemokine binding protein 2 | 481 | 3549 | 7.4 | 3011 | 310 | 0.10 | ||||
103422_at | CD1d | CD1d antigen | 1999 | 12449 | 6.2 | 22540 | 4484 | 0.20 |
Affymetrix Identifier . | Gene Symbol . | Gene Title . | Relative Expression . | . | . | Relative Expression . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | B6 FO . | B6 MZ . | Fold Difference (MZ/FO) . | MZ Id+ (0 h) . | MZ Id+ (1 h) . | Fold Difference (1 h/0 h) . | ||||
95462_at | Bzw2 | Basic leucine zipper and W2 domains 2 | 1482 | 8442 | 5.7 | 3855 | 13947 | 3.6 | ||||
92217_s_at | Gp49 | Glycoprotein 49 A/B | 161 | 2762 | 17.2 | 2530 | 13563 | 5.4 | ||||
100325_at | Gp49 | Glycoprotein 49 A/B | 394 | 5124 | 13.0 | 2530 | 13563 | 5.4 | ||||
93013_at | Id2 | Inhibitor of DNA binding 2 | 2417 | 6577 | 2.7 | 9220 | 46793 | 5.1 | ||||
95661_at | CD9 | CD9 antigen | 480 | 2677 | 5.6 | 8265 | 16347 | 2.0 | ||||
104701_at | Bhlhb2 | Basic helix-loop-helix domain containing | 272 | 1490 | 5.5 | 6307 | 22934 | 3.6 | ||||
102914_s_at | Bcl2a1 | B cell leukemia/lymphoma 2 related protein A1 | 3284 | 10193 | 3.1 | 30696 | 152568 | 5.0 | ||||
161788_f_at | S1P1 | Sphingolipid G-protein-coupled receptor 1 | 565 | 1476 | 2.6 | 129 | 18 | 0.14 | ||||
97740_at | Dusp16 | Dual specificity phosphatase 16 | 787 | 4075 | 5.2 | 312 | 9 | 0.03 | ||||
93101_s_at | Nedd4 | Neural precursor cell expressed | 660 | 3176 | 4.8 | 3668 | 565 | 0.15 | ||||
99071_at | Mpeg1 | Macrophage expressed gene 1 | 2402 | 8938 | 3.7 | 55 | 13 | 0.24 | ||||
95758_at | Scd2 | Stearoyl-Coenzyme A desaturase 2 | 4483 | 12233 | 2.7 | 6858 | 821 | 0.12 | ||||
160711_at | Decr1 | 2,4-dienoyl CoA reductase 1, mitochondrial | 187 | 553 | 3.0 | 670 | 364 | 0.54 | ||||
160069_at | Gmnn | Geminin | 422 | 1174 | 2.8 | 905 | 216 | 0.24 | ||||
102410_at | Hs3st1 | Heparan sulfate (glucosamine) 3-O-sulfotransferase | 575 | 1392 | 2.4 | 2749 | 254 | 0.09 | ||||
97949_at | Fgl2 | Fibrinogen-like protein 2 | 314 | 752 | 2.4 | 570 | 242 | 0.42 | ||||
98417_at | Mx1 | myxovirus (influenza virus) resistance 1 | 260 | 608 | 2.3 | 428 | 233 | 0.54 | ||||
160841_at | Dbp | D site albumin promoter binding protein | 239 | 540 | 2.3 | 516 | 121 | 0.23 | ||||
95387_f_at | Sema4b | Semaphorin 4B | 8465 | 17775 | 2.1 | 1495 | 271 | 0.18 | ||||
98026_g_at | Evi2a | Ecotropic viral integration site 2a | 3528 | 7178 | 2.0 | 618 | 271 | 0.44 | ||||
93430_at | Cmkor1 | Chemokine orphan receptor 1 | 78 | 4369 | 56.0 | 8291 | 1092 | 0.13 | ||||
160495_at | Ahr | Aryl-hydrocarbon receptor | 31 | 249 | 8.0 | 735 | 404 | 0.55 | ||||
98309_at | Ccbp2 | Chemokine binding protein 2 | 481 | 3549 | 7.4 | 3011 | 310 | 0.10 | ||||
103422_at | CD1d | CD1d antigen | 1999 | 12449 | 6.2 | 22540 | 4484 | 0.20 |
Id+ MZ B cells up-regulate IL-10 and Stra13 in response to R36A immunization
A number of interesting genes were identified by DNA microarray analysis on sort-purified MZ Id+ and Id− B cells at 0 and 1 h following i.v. immunization with R36A. Two of these genes that warranted further investigation were IL-10 and Stra13.
IL-10 is an immunoregulatory cytokine that plays a role in negatively regulating inflammatory immune responses, and B cells have been shown to secrete IL-10 (23). To confirm whether Id+ MZ B cells are activated to secrete IL-10 in response to R36A, we crossed the M167 heavy chain Ig Tg mouse with an IL-10/Thy1.1 reporter mouse in which all IL-10+ cells were Thy1.1+ (14), immunized with R36A, and analyzed isolated Id+ MZ B cells for the presence of IL-10 and Thy1.1 mRNA (Fig. 7,A) and the Thy1.1 reporter protein (Fig. 7,B). As expected, IL-10 and Thy1.1 mRNA increased only in the Id+ MZ B cells following immunization with R36A. The difference in degree of induction between IL-10 and Thy1.1 is most likely due to the copy number of the Thy1.1 transgene, which is estimated to be at least 12 copies (14). Stra13 is a basic helix-loop-helix domain-containing class B2 protein that is thought to be a negative regulator of B cells (24). To confirm that Stra13 is up-regulated following activation of MZ B cells, MZ Id+ B cells were isolated before and after immunization with R36A and analyzed for the level of Stra13 mRNA (Fig. 7 A). As expected, Stra13 mRNA increased only in the Id+ MZ B cells following immunization with R36A. Thus, the DNA microarray analysis of Id+ and Id− MZ B cells at 0 and 1 h following immunization with R36A identified multiple genes of interest that were rapidly up-regulated or down-regulated after activation, including IL-10 and Stra13.
IL-10 and Stra13 are increased following R36A immunization. M167 Tg mice were crossed with an IL-10/Thy1.1 reporter mouse and immunized i.v. with R36A. MZ Id+ B cells were sort purified at 0, 1, and 4 h after immunization and total RNA was isolated. A, RT-PCR was performed using gene-specific primers for IL-10, Thy1.1, Stra13, and actin. B, The expression level of Thy1.1 was determined via FACS analysis on gated MZ Id+ B cells at 24 h following R36A immunization. MZ Id+ B cells were ∼5% (PBS) and 20% (R36A) positive for Thy1.1, respectively.
IL-10 and Stra13 are increased following R36A immunization. M167 Tg mice were crossed with an IL-10/Thy1.1 reporter mouse and immunized i.v. with R36A. MZ Id+ B cells were sort purified at 0, 1, and 4 h after immunization and total RNA was isolated. A, RT-PCR was performed using gene-specific primers for IL-10, Thy1.1, Stra13, and actin. B, The expression level of Thy1.1 was determined via FACS analysis on gated MZ Id+ B cells at 24 h following R36A immunization. MZ Id+ B cells were ∼5% (PBS) and 20% (R36A) positive for Thy1.1, respectively.
Discussion
Previous data studying FO and MZ B cells have shown that these B cell subsets differ based on their anatomical location in the spleen, cellular surface molecule expression, and effector functions (reviewed in Ref. 1). We set out to identify new genes and pathways that are differentially expressed between FO and MZ B cells and those that were specifically up-regulated or down-regulated within each subset following activation. DNA microarray allows for a high throughput analysis of genomic expression differences between two sample populations. This approach identified 181 genes differentially expressed between resting MZ and FO B cells. Ninety-nine genes were more highly expressed in MZ B cells while 82 genes were more highly expressed in FO B cells. In addition, DNA microarray analysis of MZ Id+ and Id− B cells before (0 h) and after (1 h) R36A immunization revealed many new genes and pathways specifically regulated in the MZ Id+ B cells. These findings further our understanding of MZ and FO B cell biology while at the same time identifying new candidate genes and pathways to study.
The MZ vs FO B cell microarray used cells that were isolated by gating on B220 and then sorted based on surface expression patterns of CD21highCD23low for MZ B cells and CD21lowCD23high for FO B cells. As expected, our DNA microarray results showed higher mRNA expression of CD21 and lower expression of CD23 in MZ B cells relative to FO B cells. MZ B cells are known to express surface CD9 and CD1d whereas FO B cells express little to no CD9 and CD1d (9, 25). Similarly, our microarray results showed a higher expression of CD9 and CD1d on MZ B cells relative to FO B cells. Furthermore, S1P1 and S1P3 were previously shown to be expressed at higher levels on MZ B cells relative to FO B cells, while S1P4 was expressed higher on FO B cells (19). Our data were again consistent with what has been shown in the literature, showing higher expression of S1P1 and S1P3 on MZ B cells and higher expression of S1P4 on FO B cells. Taken together, it appears that our DNA microarray data agree with what has been shown in the literature with respect to known phenotypic differences between MZ and FO B cells, suggesting that our sorted B cell populations were pure and our DNA microarray method of analysis is valid.
One interesting gene more highly expressed in MZ B cells relative to FO B cells was RGS10. RGS10 has been previously confirmed to be specifically expressed in MZ B cells (mRNA) as well as plasma cells (26). RGS10 attenuates signaling pathways via increased GTPase activity to specific G α subunits (27). Phosphorylation by protein kinase A induces its localization to the nucleus (28). Recently, RGS10−/− mice were reported that exhibited severe osteopetrosis and impaired osteoclast differentiation resulting from the loss of [Ca2+]i oscillation regulation (29), although no immune characterization was reported. Although RGS10 was more highly expressed in resting MZ B cells relative to FO B cells, RGS10 mRNA was not found to be regulated following activation in MZ Id+ B cells. However, because chemokine receptors are G protein coupled, a protein that regulates their signaling capacity might play an important role in localization, maintenance, or migration of MZ B cells. For example, RGS1, RGS3, and RGS4 introduction into B cell lines dramatically alters chemokine-induced cell migration (30, 31, 32). Taken together, MZ B cell-specific expression of RGS10 potentially plays a role in regulating the ability to respond to chemokine signals and might play a role in MZ B cell localization.
An additional gene more highly expressed in MZ B cells was D6. D6 is proposed to be a decoy chemokine receptor that has the ability to bind, internalize, and degrade chemokine ligands through a β-arrestin-dependent mechanism, a function termed chemokine scavenging (33, 34, 35, 36). Interestingly, our results show that D6 is more highly expressed in resting MZ B cells relative to FO B cells and that D6 is rapidly down-regulated (10-fold) following activation. Given its proposed property of a chemokine sink and the fact that D6 has not been shown to signal intracellularly, the potential exists that D6 expression on the surface of MZ B cells is involved in keeping them properly localized within the splenic microenvironment. Rapid down-regulation of D6 after activation potentially enhances the migration of MZ B cells to the T:B cell border. D6 expression has been reported in B cells previously (37), although the differential expression in B cell subsets was not investigated. Thus, D6 appears to be an interesting candidate gene potentially involved in MZ B cell localization, maintenance, and/or migration.
Our second DNA microarray experiment was aimed at identifying genes that were specifically up-regulated or down-regulated following activation. Using the M167 Tg mouse, we sort purified MZ Id+ and Id− B cells at 0 and 1 h after i.v. immunization with R36A. S1P1 transcripts were rapidly down-regulated (7.0-fold) following activation only in the Id+ MZ B cells, which is in agreement with the findings of Cyster and colleagues (19). S1P1 has been shown to play a role in the migration of MZ B cells to the T:B border following activation. In addition, the MZ B cell-specific marker, CD9, was increased 2.0-fold following activation, consistent with our previous findings (9). Of additional interest, only the MZ Id+ and not the MZ Id− B cells rapidly increased antiapoptotic genes and decreased proapoptotic genes, a phenotype consistent with cellular activation. This shows a remarkable degree of Ag specificity in that virtually no concurrent increases were detected in the MZ Id+ and Id− B cell populations at 1 h. Our microarray results appear to agree with a number of well studied genes already published in the literature with respect to MZ B cells, indicating that both our cell sort and microarray analyses are accurate. Consequently, further analysis and weight can be given to the other genes found to be regulated following immunization.
One interesting gene identified by microarray analysis to be specifically increased only in the Id+ MZ B cells was IL-10. Interestingly, MZ B cells have been suggested as playing an immunoregulatory role through secretion of IL-10 (38). IL-10 is an immunoregulatory cytokine that plays an important role in negatively regulating inflammatory immune responses. A variety of cells are capable of producing IL-10, including Th2, regulatory T (Treg), B-1, and MZ B cells (39). The effects of IL-10 are mainly immunosuppressive but also depend on which cell type is being affected by IL-10. In experimental autoimmune encephalitis, an experimental model of multiple sclerosis, one study suggested that B cells regulate regulatory T cells via B7 and IL-10 to suppress autoimmune inflammation (40). Besides the immunosuppressive role of IL-10, it has been suggested to play a role in B cell Ab production. The addition of IL-10 to human B cell cultures is reported to increase class switch recombination and the production of IgA and IgG (41, 42, 43). However, the specific B cell subset, its location in the spleen before and after stimulation, and the signals required to produce IL-10 are not fully understood.
Stra13 was another interesting gene that was rapidly up-regulated following activation. Stra13 is a basic helix-loop-helix domain-containing class B2 protein that is thought to be a negative regulator of B cells (24). Stra13−/− mice develop autoimmune disease characterized by the accumulation of spontaneously activated T and B cells, circulating autoantibodies, infiltration of T and B cells into several organs, and immune complex deposition in glomeruli (44). Stra13 transgenic mice show impaired development of T and B cells, with the expansion of progenitor B and T cells most strongly affected (45). Of interest, Stra13 is developmentally regulated in B cells and decreases after activation in germinal center B cells (45). Our results in Id+ MZ B cells show that Stra13 increases after activation, although the functional relevance of this regulation is currently unknown.
The goal of this study was twofold: to identify genes that were differentially expressed between resting FO and MZ B cells and to identify genes that were specifically regulated in MZ Id+ B cells following activation. The results generated give a genome-wide look at the genes differentially expressed in FO and MZ B cells that potentially account for their differences in localization and function. Furthermore, the second microarray gave a comparative snapshot at 1 h of the gene expression profiles between Ag-specific vs nonspecific MZ B cells. One major problem with DNA microarray analysis is that many of the genes reported have not been studied, making conclusions difficult. However, a multitude of data is presented here with respect to FO and MZ B cell biology that will facilitate identification of new genes and pathways to explore.
Acknowledgment
We gratefully acknowledge Dr. Casey Weaver (University of Alabama at Birmingham) for generously sharing the Thy1.1/IL-10 reporter mice.
Disclosures
The authors have no financial conflict of interest.
Genes differentially expressed between FO and MZ B cells in B6, SWR, and C3H mouse strains
Affymetrix Identifier . | Gene Symbol . | Gene Title . | Relative Expression . | . | . | Relative Expression . | . | . | Relative Expression . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | B6 FO . | B6 MZ . | Fold Difference (MZ/FO) . | SWR FO . | SWR MZ . | Fold Difference (MZ/FO) . | C3H FO . | C3H MZ . | Fold Difference (MZ/FO) . | ||||||
93430_at | Cmkor1 | Chemokine orphan receptor 1 | 78 | 4369 | 56.0 | 12 | 2081 | 178.5 | 107 | 3147 | 29.3 | ||||||
97967_at | Plxnd1 | Plexin D1 | 70 | 3800 | 54.4 | 70 | 107 | 1.5 | 44 | 50 | 1.1 | ||||||
102910_at | Abcb1a | ATP-binding cassette, sub-family B (MDR/TAP) | 48 | 953 | 19.8 | 28 | 716 | 25.3 | 52 | 596 | 11.6 | ||||||
92217_s_at | Gp49 | Glycoprotein 49 A/B | 161 | 2762 | 17.2 | 559 | 2146 | 3.8 | 582 | 2470 | 4.2 | ||||||
101587_at | Ephx1 | Epoxide hydrolase 1, microsomal | 235 | 3410 | 14.5 | 3682 | 4366 | 1.2 | 4074 | 4099 | 1.0 | ||||||
100325_at | Gp49 | Glycoprotein 49 A/B | 394 | 5124 | 13.0 | 716 | 4134 | 5.8 | 1009 | 4883 | 4.8 | ||||||
96865_at | Marcks | Myristoylated alanine rich protein kinase C substrate | 1183 | 14871 | 12.6 | 952 | 3840 | 4.0 | 1085 | 5057 | 4.7 | ||||||
97105_at | C230027N18Rik | RIKEN cDNA C230027N18 gene | 269 | 3142 | 11.7 | 564 | 2822 | 5.0 | 417 | 2519 | 6.0 | ||||||
101923_at | Pla2g7 | Phospholipase A2, group VII | 284 | 2408 | 8.5 | 24 | 669 | 28.2 | 89 | 1230 | 13.9 | ||||||
160495_at | Ahr | Aryl-hydrocarbon receptor | 31 | 249 | 8.0 | 461 | 1477 | 3.2 | 737 | 2594 | 3.5 | ||||||
93411_at | Sema7a | Semaphorin 7A | 788 | 6214 | 7.9 | 1038 | 4241 | 4.1 | 826 | 2926 | 3.5 | ||||||
102722_g_at | IgG3 | Ig γ-3 heavy chain precursor | 310 | 2436 | 7.9 | 829 | 1541 | 1.9 | 1281 | 2699 | 2.1 | ||||||
100912_at | Dph5 | DPH5 homolog (S. cerevisiae) | 1229 | 9553 | 7.8 | 687 | 3390 | 4.9 | 954 | 4768 | 5.0 | ||||||
98309_at | Ccbp2 | Chemokine binding protein 2 | 481 | 3549 | 7.4 | 85 | 895 | 10.5 | 343 | 526 | 1.5 | ||||||
97487_at | Serpine2 | Serine (or cysteine) peptidase inhibitor | 219 | 1377 | 6.3 | 148 | 747 | 5.1 | 203 | 1708 | 8.4 | ||||||
103422_at | CD1d | CD1d antigen | 1999 | 12449 | 6.2 | 1339 | 8025 | 6.0 | 2393 | 5418 | 2.3 | ||||||
161058_f_at | R74862 | Expressed sequence R74862 | 52 | 313 | 6.1 | 17 | 131 | 7.8 | 79 | 184 | 2.3 | ||||||
92356_at | Ptpn22 | Protein tyrosine phosphatase, nonreceptor type 22 | 1775 | 10160 | 5.7 | 4668 | 13103 | 2.8 | 7670 | 20357 | 2.7 | ||||||
95462_at | Bzw2 | Basic leucine zipper and W2 domains 2 | 1482 | 8442 | 5.7 | 1678 | 4786 | 2.9 | 3611 | 17670 | 4.9 | ||||||
95661_at | CD9 | CD9 antigen | 480 | 2677 | 5.6 | 127 | 2212 | 17.4 | 550 | 2737 | 5.0 | ||||||
104701_at | Bhlhd2 | Basic helix-loop-helix domain containing | 272 | 1490 | 5.5 | 5828 | 8002 | 1.4 | 5729 | 6426 | 1.1 | ||||||
160629_at | Res10 | Regulator of G-protein signaling 10 | 450 | 2368 | 5.3 | 135 | 1234 | 9.2 | 419 | 838 | 2.0 | ||||||
97740_at | Dusp16 | Dual specificity phosphatase 16 | 787 | 4075 | 5.2 | 1214 | 3889 | 3.2 | 1173 | 4992 | 4.3 | ||||||
102924_at | Dtx1 | Deltex 1 homolog (Drosophila) | 7962 | 39206 | 4.9 | 9975 | 29520 | 3.0 | 7015 | 31023 | 4.4 | ||||||
93101_s_at | Nedd4 | Neural precursor cell expressed | 660 | 3176 | 4.8 | 480 | 1244 | 2.6 | 645 | 1626 | 2.5 | ||||||
93195_at | Mfhas1 | Malignant fibrous histiocytoma amplified sequence | 1143 | 5462 | 4.8 | 2857 | 2424 | 0.8 | 3446 | 3592 | 1.0 | ||||||
101584_at | Rsu1 | Ras suppressor protein 1 | 2028 | 9591 | 4.7 | 2007 | 4411 | 2.2 | 1809 | 7286 | 4.0 | ||||||
102721_at | IgG3 | Ig γ-3 heavy chain precursor | 812 | 3415 | 4.2 | 1344 | 1948 | 1.4 | 1766 | 2882 | 1.6 | ||||||
98433_at | Bid | BH3 interacting domain death agonist | 1622 | 6473 | 4.0 | 689 | 1926 | 2.8 | 495 | 1277 | 2.6 | ||||||
101516_at | CD59a | CD59a antigen | 527 | 2091 | 4.0 | 410 | 1617 | 3.9 | 533 | 1817 | 3.4 | ||||||
102644_at | Mdfic | MyoD family inhibitor domain containing | 784 | 3083 | 3.9 | 533 | 1751 | 3.3 | 1426 | 2847 | 2.0 | ||||||
99071_at | Mpeg 1 | Macrophage expressed gene 1 | 2402 | 8938 | 3.7 | 491 | 1982 | 4.0 | 1743 | 5743 | 3.3 | ||||||
160487_at | Myl4 | Myosin, light polypeptide 4 | 942 | 3407 | 3.6 | 2627 | 6593 | 2.5 | 2335 | 6783 | 2.9 | ||||||
102223_at | Ppl | Periplakin | 1294 | 4673 | 3.6 | 1482 | 2177 | 1.5 | 1404 | 2906 | 2.1 | ||||||
96283_at | Itm2C | integral membrane protein 2C | 1458 | 5254 | 3.6 | 881 | 1943 | 2.2 | 1073 | 3249 | 3.0 | ||||||
161765_f_at | Res10 | Regulator of G-protein signaling 10 | 535 | 1792 | 3.4 | 365 | 963 | 2.6 | 290 | 733 | 2.5 | ||||||
94958_at | 1110013L07Rik | RIKEN cDNA 1110013LC7 gene | 486 | 1575 | 3.2 | 220 | 548 | 2.5 | 129 | 336 | 2.6 | ||||||
101897_g_at | CD1d | CD1d antigen | 5039 | 16158 | 3.2 | 2039 | 6961 | 3.4 | 3129 | 7065 | 2.3 | ||||||
102289_r_at | CD21 | Complement receptor 2 | 931 | 2964 | 3.2 | 2116 | 4053 | 1.9 | 1348 | 3034 | 2.3 | ||||||
97460_at | Ube2r2 | Ubiquitin-conjugating enzyme E2R 2 | 9117 | 28949 | 3.2 | 5367 | 13029 | 2.4 | 10403 | 17285 | 1.7 | ||||||
102914_s_at | Bcl2a1 | B cell leukemia/lymphoma 2 related protein A1 | 3284 | 10193 | 3.1 | 15571 | 28095 | 1.8 | 22037 | 32334 | 1.5 | ||||||
95084_f_at | Grhpr | Glyoxylate reductase/hydroxypyruvate reductase | 2362 | 7175 | 3.0 | 1612 | 3071 | 1.9 | 1565 | 2941 | 1.9 | ||||||
160711_at | Decr1 | 2,4-Dienoyl CoA reductase 1, mitochondrial | 187 | 553 | 3.0 | 267 | 270 | 1.0 | 201 | 437 | 2.2 | ||||||
100397_at | DAP12 | TYRO protein tyrosine kinase binding protein | 4658 | 13714 | 2.9 | 751 | 2767 | 3.7 | 2109 | 3985 | 1.9 | ||||||
96735_at | Stard10 | START domain containing 10 | 2538 | 7449 | 2.9 | 2026 | 2932 | 1.4 | 1349 | 1734 | 1.3 | ||||||
92587_at | Fdx1 | Ferredoxin 1 | 1631 | 4714 | 2.9 | 1510 | 2957 | 2.0 | 2305 | 3744 | 1.6 | ||||||
104298_at | 2310044G17Rik | RIKEN cDNA 2310044G17 gene | 1290 | 3689 | 2.9 | 1797 | 2292 | 1.3 | 1320 | 4032 | 3.1 | ||||||
104299_at | Zdhhc14 | Zinc finger, DHHC domain containing 14 | 1176 | 3359 | 2.9 | 328 | 651 | 2.0 | 794 | 1865 | 2.4 | ||||||
160941_at | Pde8a | Phosphodiesterase 8A | 383 | 1085 | 2.8 | 690 | 1016 | 1.5 | 414 | 1013 | 2.4 | ||||||
98822_at | Gip2 | Interferon, α-inducible protein | 1381 | 3885 | 2.8 | 1335 | 2609 | 2.0 | 1244 | 3258 | 2.6 | ||||||
98033_at | 1100001H23Rik | RIKEN cDNA 1100001H23 gene | 4159 | 11695 | 2.8 | 4474 | 7701 | 1.7 | 6414 | 9391 | 1.5 | ||||||
94186_at | Traf1 | TNFR-associated factor 1 | 1612 | 4530 | 2.8 | 1740 | 4258 | 2.4 | 1538 | 4368 | 2.8 | ||||||
160069_at | Gmnn | Geminin | 422 | 1174 | 2.8 | 376 | 323 | 0.9 | 229 | 445 | 1.9 | ||||||
95758_at | Scd2 | Stearoyl-coenzyme A desaturase 2 | 4483 | 12233 | 2.7 | 1094 | 2501 | 2.3 | 703 | 1147 | 1.6 | ||||||
100880_at | 9830147J24Rik | RIKEN cDNA 9830147J24 gene | 1271 | 3463 | 2.7 | 733 | 951 | 1.3 | 676 | 1657 | 2.5 | ||||||
92850_at | Rrbp1 | Ribosome binding protein 1 | 2821 | 7681 | 2.7 | 3262 | 6051 | 1.9 | 2147 | 5191 | 2.4 | ||||||
93013_at | Id2 | Inhibitor of DNA binding 2 | 2417 | 6577 | 2.7 | 2786 | 11282 | 4.0 | 6513 | 15250 | 2.3 | ||||||
93261_at | lgmn | Legumain | 2555 | 6932 | 2.7 | 1582 | 3143 | 2.0 | 1838 | 2832 | 1.5 | ||||||
93833_s_at | Hist1h2bc | Histone 1, H2bc | 773 | 2093 | 2.7 | 617 | 697 | 1.1 | 1189 | 536 | 0.5 | ||||||
96688_at | Tmem77 | Transmembrane protein 77 | 728 | 1935 | 2.7 | 320 | 860 | 2.7 | 572 | 1211 | 2.1 | ||||||
160762_at | Abr | Active BCR-related gene | 706 | 1845 | 2.6 | 736 | 2020 | 2.7 | 620 | 1084 | 1.7 | ||||||
161788_f_at | SlP1 | Sphingolipid G protein-coupled receptor 1 | 565 | 1476 | 2.6 | 1332 | 747 | 0.6 | 936 | 562 | 0.6 | ||||||
93483_at | Hck | Hemopoietic cell kinase | 5919 | 15436 | 2.6 | 2869 | 9495 | 3.3 | 2498 | 6070 | 2.4 | ||||||
94995_at | A030007L17Rik | RIKEN cDNA A030007L17 gene | 848 | 2186 | 2.6 | 926 | 734 | 0.8 | 1184 | 817 | 0.7 | ||||||
92925_at | Cebpb | CCAAT/enhancer binding protein (C/EBP), beta | 1911 | 4882 | 2.6 | 12638 | 12321 | 1.0 | 20455 | 13386 | 0.7 | ||||||
100516_at | Chka | Choline kinase α | 874 | 2195 | 2.5 | 1728 | 1646 | 1.0 | 880 | 728 | 0.8 | ||||||
104712_at | Myc | Myelocytomatosis oncogene | 906 | 2242 | 2.5 | 4293 | 11096 | 2.6 | 4967 | 12611 | 2.5 | ||||||
92352_at | SlP3 | Sphingolipid G protein-coupled receptor 3 | 1522 | 3765 | 2.5 | 1223 | 1791 | 1.5 | 1370 | 2343 | 1.7 | ||||||
98931_at | Gns | Glucosamine (N-acetyl)-6-sulfatase | 2595 | 6366 | 2.5 | 3560 | 4612 | 1.3 | 2685 | 4575 | 1.7 | ||||||
102410_at | Hs3st1 | Heparan sulfate (glucosamine) 3-O-sulfotransferase | 575 | 1392 | 2.4 | 510 | 2503 | 4.9 | 9768 | 14854 | 1.5 | ||||||
(Table continues) |
Affymetrix Identifier . | Gene Symbol . | Gene Title . | Relative Expression . | . | . | Relative Expression . | . | . | Relative Expression . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | B6 FO . | B6 MZ . | Fold Difference (MZ/FO) . | SWR FO . | SWR MZ . | Fold Difference (MZ/FO) . | C3H FO . | C3H MZ . | Fold Difference (MZ/FO) . | ||||||
93430_at | Cmkor1 | Chemokine orphan receptor 1 | 78 | 4369 | 56.0 | 12 | 2081 | 178.5 | 107 | 3147 | 29.3 | ||||||
97967_at | Plxnd1 | Plexin D1 | 70 | 3800 | 54.4 | 70 | 107 | 1.5 | 44 | 50 | 1.1 | ||||||
102910_at | Abcb1a | ATP-binding cassette, sub-family B (MDR/TAP) | 48 | 953 | 19.8 | 28 | 716 | 25.3 | 52 | 596 | 11.6 | ||||||
92217_s_at | Gp49 | Glycoprotein 49 A/B | 161 | 2762 | 17.2 | 559 | 2146 | 3.8 | 582 | 2470 | 4.2 | ||||||
101587_at | Ephx1 | Epoxide hydrolase 1, microsomal | 235 | 3410 | 14.5 | 3682 | 4366 | 1.2 | 4074 | 4099 | 1.0 | ||||||
100325_at | Gp49 | Glycoprotein 49 A/B | 394 | 5124 | 13.0 | 716 | 4134 | 5.8 | 1009 | 4883 | 4.8 | ||||||
96865_at | Marcks | Myristoylated alanine rich protein kinase C substrate | 1183 | 14871 | 12.6 | 952 | 3840 | 4.0 | 1085 | 5057 | 4.7 | ||||||
97105_at | C230027N18Rik | RIKEN cDNA C230027N18 gene | 269 | 3142 | 11.7 | 564 | 2822 | 5.0 | 417 | 2519 | 6.0 | ||||||
101923_at | Pla2g7 | Phospholipase A2, group VII | 284 | 2408 | 8.5 | 24 | 669 | 28.2 | 89 | 1230 | 13.9 | ||||||
160495_at | Ahr | Aryl-hydrocarbon receptor | 31 | 249 | 8.0 | 461 | 1477 | 3.2 | 737 | 2594 | 3.5 | ||||||
93411_at | Sema7a | Semaphorin 7A | 788 | 6214 | 7.9 | 1038 | 4241 | 4.1 | 826 | 2926 | 3.5 | ||||||
102722_g_at | IgG3 | Ig γ-3 heavy chain precursor | 310 | 2436 | 7.9 | 829 | 1541 | 1.9 | 1281 | 2699 | 2.1 | ||||||
100912_at | Dph5 | DPH5 homolog (S. cerevisiae) | 1229 | 9553 | 7.8 | 687 | 3390 | 4.9 | 954 | 4768 | 5.0 | ||||||
98309_at | Ccbp2 | Chemokine binding protein 2 | 481 | 3549 | 7.4 | 85 | 895 | 10.5 | 343 | 526 | 1.5 | ||||||
97487_at | Serpine2 | Serine (or cysteine) peptidase inhibitor | 219 | 1377 | 6.3 | 148 | 747 | 5.1 | 203 | 1708 | 8.4 | ||||||
103422_at | CD1d | CD1d antigen | 1999 | 12449 | 6.2 | 1339 | 8025 | 6.0 | 2393 | 5418 | 2.3 | ||||||
161058_f_at | R74862 | Expressed sequence R74862 | 52 | 313 | 6.1 | 17 | 131 | 7.8 | 79 | 184 | 2.3 | ||||||
92356_at | Ptpn22 | Protein tyrosine phosphatase, nonreceptor type 22 | 1775 | 10160 | 5.7 | 4668 | 13103 | 2.8 | 7670 | 20357 | 2.7 | ||||||
95462_at | Bzw2 | Basic leucine zipper and W2 domains 2 | 1482 | 8442 | 5.7 | 1678 | 4786 | 2.9 | 3611 | 17670 | 4.9 | ||||||
95661_at | CD9 | CD9 antigen | 480 | 2677 | 5.6 | 127 | 2212 | 17.4 | 550 | 2737 | 5.0 | ||||||
104701_at | Bhlhd2 | Basic helix-loop-helix domain containing | 272 | 1490 | 5.5 | 5828 | 8002 | 1.4 | 5729 | 6426 | 1.1 | ||||||
160629_at | Res10 | Regulator of G-protein signaling 10 | 450 | 2368 | 5.3 | 135 | 1234 | 9.2 | 419 | 838 | 2.0 | ||||||
97740_at | Dusp16 | Dual specificity phosphatase 16 | 787 | 4075 | 5.2 | 1214 | 3889 | 3.2 | 1173 | 4992 | 4.3 | ||||||
102924_at | Dtx1 | Deltex 1 homolog (Drosophila) | 7962 | 39206 | 4.9 | 9975 | 29520 | 3.0 | 7015 | 31023 | 4.4 | ||||||
93101_s_at | Nedd4 | Neural precursor cell expressed | 660 | 3176 | 4.8 | 480 | 1244 | 2.6 | 645 | 1626 | 2.5 | ||||||
93195_at | Mfhas1 | Malignant fibrous histiocytoma amplified sequence | 1143 | 5462 | 4.8 | 2857 | 2424 | 0.8 | 3446 | 3592 | 1.0 | ||||||
101584_at | Rsu1 | Ras suppressor protein 1 | 2028 | 9591 | 4.7 | 2007 | 4411 | 2.2 | 1809 | 7286 | 4.0 | ||||||
102721_at | IgG3 | Ig γ-3 heavy chain precursor | 812 | 3415 | 4.2 | 1344 | 1948 | 1.4 | 1766 | 2882 | 1.6 | ||||||
98433_at | Bid | BH3 interacting domain death agonist | 1622 | 6473 | 4.0 | 689 | 1926 | 2.8 | 495 | 1277 | 2.6 | ||||||
101516_at | CD59a | CD59a antigen | 527 | 2091 | 4.0 | 410 | 1617 | 3.9 | 533 | 1817 | 3.4 | ||||||
102644_at | Mdfic | MyoD family inhibitor domain containing | 784 | 3083 | 3.9 | 533 | 1751 | 3.3 | 1426 | 2847 | 2.0 | ||||||
99071_at | Mpeg 1 | Macrophage expressed gene 1 | 2402 | 8938 | 3.7 | 491 | 1982 | 4.0 | 1743 | 5743 | 3.3 | ||||||
160487_at | Myl4 | Myosin, light polypeptide 4 | 942 | 3407 | 3.6 | 2627 | 6593 | 2.5 | 2335 | 6783 | 2.9 | ||||||
102223_at | Ppl | Periplakin | 1294 | 4673 | 3.6 | 1482 | 2177 | 1.5 | 1404 | 2906 | 2.1 | ||||||
96283_at | Itm2C | integral membrane protein 2C | 1458 | 5254 | 3.6 | 881 | 1943 | 2.2 | 1073 | 3249 | 3.0 | ||||||
161765_f_at | Res10 | Regulator of G-protein signaling 10 | 535 | 1792 | 3.4 | 365 | 963 | 2.6 | 290 | 733 | 2.5 | ||||||
94958_at | 1110013L07Rik | RIKEN cDNA 1110013LC7 gene | 486 | 1575 | 3.2 | 220 | 548 | 2.5 | 129 | 336 | 2.6 | ||||||
101897_g_at | CD1d | CD1d antigen | 5039 | 16158 | 3.2 | 2039 | 6961 | 3.4 | 3129 | 7065 | 2.3 | ||||||
102289_r_at | CD21 | Complement receptor 2 | 931 | 2964 | 3.2 | 2116 | 4053 | 1.9 | 1348 | 3034 | 2.3 | ||||||
97460_at | Ube2r2 | Ubiquitin-conjugating enzyme E2R 2 | 9117 | 28949 | 3.2 | 5367 | 13029 | 2.4 | 10403 | 17285 | 1.7 | ||||||
102914_s_at | Bcl2a1 | B cell leukemia/lymphoma 2 related protein A1 | 3284 | 10193 | 3.1 | 15571 | 28095 | 1.8 | 22037 | 32334 | 1.5 | ||||||
95084_f_at | Grhpr | Glyoxylate reductase/hydroxypyruvate reductase | 2362 | 7175 | 3.0 | 1612 | 3071 | 1.9 | 1565 | 2941 | 1.9 | ||||||
160711_at | Decr1 | 2,4-Dienoyl CoA reductase 1, mitochondrial | 187 | 553 | 3.0 | 267 | 270 | 1.0 | 201 | 437 | 2.2 | ||||||
100397_at | DAP12 | TYRO protein tyrosine kinase binding protein | 4658 | 13714 | 2.9 | 751 | 2767 | 3.7 | 2109 | 3985 | 1.9 | ||||||
96735_at | Stard10 | START domain containing 10 | 2538 | 7449 | 2.9 | 2026 | 2932 | 1.4 | 1349 | 1734 | 1.3 | ||||||
92587_at | Fdx1 | Ferredoxin 1 | 1631 | 4714 | 2.9 | 1510 | 2957 | 2.0 | 2305 | 3744 | 1.6 | ||||||
104298_at | 2310044G17Rik | RIKEN cDNA 2310044G17 gene | 1290 | 3689 | 2.9 | 1797 | 2292 | 1.3 | 1320 | 4032 | 3.1 | ||||||
104299_at | Zdhhc14 | Zinc finger, DHHC domain containing 14 | 1176 | 3359 | 2.9 | 328 | 651 | 2.0 | 794 | 1865 | 2.4 | ||||||
160941_at | Pde8a | Phosphodiesterase 8A | 383 | 1085 | 2.8 | 690 | 1016 | 1.5 | 414 | 1013 | 2.4 | ||||||
98822_at | Gip2 | Interferon, α-inducible protein | 1381 | 3885 | 2.8 | 1335 | 2609 | 2.0 | 1244 | 3258 | 2.6 | ||||||
98033_at | 1100001H23Rik | RIKEN cDNA 1100001H23 gene | 4159 | 11695 | 2.8 | 4474 | 7701 | 1.7 | 6414 | 9391 | 1.5 | ||||||
94186_at | Traf1 | TNFR-associated factor 1 | 1612 | 4530 | 2.8 | 1740 | 4258 | 2.4 | 1538 | 4368 | 2.8 | ||||||
160069_at | Gmnn | Geminin | 422 | 1174 | 2.8 | 376 | 323 | 0.9 | 229 | 445 | 1.9 | ||||||
95758_at | Scd2 | Stearoyl-coenzyme A desaturase 2 | 4483 | 12233 | 2.7 | 1094 | 2501 | 2.3 | 703 | 1147 | 1.6 | ||||||
100880_at | 9830147J24Rik | RIKEN cDNA 9830147J24 gene | 1271 | 3463 | 2.7 | 733 | 951 | 1.3 | 676 | 1657 | 2.5 | ||||||
92850_at | Rrbp1 | Ribosome binding protein 1 | 2821 | 7681 | 2.7 | 3262 | 6051 | 1.9 | 2147 | 5191 | 2.4 | ||||||
93013_at | Id2 | Inhibitor of DNA binding 2 | 2417 | 6577 | 2.7 | 2786 | 11282 | 4.0 | 6513 | 15250 | 2.3 | ||||||
93261_at | lgmn | Legumain | 2555 | 6932 | 2.7 | 1582 | 3143 | 2.0 | 1838 | 2832 | 1.5 | ||||||
93833_s_at | Hist1h2bc | Histone 1, H2bc | 773 | 2093 | 2.7 | 617 | 697 | 1.1 | 1189 | 536 | 0.5 | ||||||
96688_at | Tmem77 | Transmembrane protein 77 | 728 | 1935 | 2.7 | 320 | 860 | 2.7 | 572 | 1211 | 2.1 | ||||||
160762_at | Abr | Active BCR-related gene | 706 | 1845 | 2.6 | 736 | 2020 | 2.7 | 620 | 1084 | 1.7 | ||||||
161788_f_at | SlP1 | Sphingolipid G protein-coupled receptor 1 | 565 | 1476 | 2.6 | 1332 | 747 | 0.6 | 936 | 562 | 0.6 | ||||||
93483_at | Hck | Hemopoietic cell kinase | 5919 | 15436 | 2.6 | 2869 | 9495 | 3.3 | 2498 | 6070 | 2.4 | ||||||
94995_at | A030007L17Rik | RIKEN cDNA A030007L17 gene | 848 | 2186 | 2.6 | 926 | 734 | 0.8 | 1184 | 817 | 0.7 | ||||||
92925_at | Cebpb | CCAAT/enhancer binding protein (C/EBP), beta | 1911 | 4882 | 2.6 | 12638 | 12321 | 1.0 | 20455 | 13386 | 0.7 | ||||||
100516_at | Chka | Choline kinase α | 874 | 2195 | 2.5 | 1728 | 1646 | 1.0 | 880 | 728 | 0.8 | ||||||
104712_at | Myc | Myelocytomatosis oncogene | 906 | 2242 | 2.5 | 4293 | 11096 | 2.6 | 4967 | 12611 | 2.5 | ||||||
92352_at | SlP3 | Sphingolipid G protein-coupled receptor 3 | 1522 | 3765 | 2.5 | 1223 | 1791 | 1.5 | 1370 | 2343 | 1.7 | ||||||
98931_at | Gns | Glucosamine (N-acetyl)-6-sulfatase | 2595 | 6366 | 2.5 | 3560 | 4612 | 1.3 | 2685 | 4575 | 1.7 | ||||||
102410_at | Hs3st1 | Heparan sulfate (glucosamine) 3-O-sulfotransferase | 575 | 1392 | 2.4 | 510 | 2503 | 4.9 | 9768 | 14854 | 1.5 | ||||||
(Table continues) |
(Continued)
Affymetrix Identifier . | Gene Symbol . | Gene Title . | Relative Expression . | . | . | Relative Expression . | . | . | Relative Expression . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | B6 FO . | B6 MZ . | Fold Difference (MZ/FO) . | SWR FO . | SWR MZ . | Fold Difference (MZ/FO) . | C3H FO . | C3H MZ . | Fold Difference (MZ/FO) . | ||||||
97949_at | Fg12 | Fibrinogen-like protein 2 | 314 | 752 | 2.4 | 126 | 541 | 4.3 | 234 | 1144 | 4.9 | ||||||
101495_at | CD81 | CD81 antigen | 8639 | 20584 | 2.4 | 5250 | 7579 | 1.4 | 5062 | 8355 | 1.7 | ||||||
98092_at | Plac8 | Placenta-specific 8 | 56686 | 134293 | 2.4 | 37938 | 75591 | 2.0 | 29999 | 77352 | 2.6 | ||||||
98417_at | Mx1 | Myxovirus (influenza virus) resistance 1 | 260 | 608 | 2.3 | 190 | 309 | 1.6 | 104 | 206 | 2.0 | ||||||
103459_at | Slc39a6 | Solute carrier family 39 (metal ion transporter) | 862 | 2007 | 2.3 | 1337 | 2067 | 1.5 | 971 | 1825 | 1.9 | ||||||
95358_at | Pip5k2a | Phosphatidylinositol-4-phosphate 5-kinase | 4119 | 9541 | 2.3 | 2763 | 5125 | 1.9 | 3479 | 6084 | 1.7 | ||||||
93084_at | Slc25a4 | Solute carrier family 25 (ademine translocator) | 4789 | 11081 | 2.3 | 3596 | 5997 | 1.7 | 6120 | 7659 | 1.3 | ||||||
102217_at | Gprk5 | G protein-coupled receptor kinase 5 | 772 | 1784 | 2.3 | 450 | 1351 | 3.0 | 601 | 668 | 1.1 |
Affymetrix Identifier . | Gene Symbol . | Gene Title . | Relative Expression . | . | . | Relative Expression . | . | . | Relative Expression . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | B6 FO . | B6 MZ . | Fold Difference (MZ/FO) . | SWR FO . | SWR MZ . | Fold Difference (MZ/FO) . | C3H FO . | C3H MZ . | Fold Difference (MZ/FO) . | ||||||
97949_at | Fg12 | Fibrinogen-like protein 2 | 314 | 752 | 2.4 | 126 | 541 | 4.3 | 234 | 1144 | 4.9 | ||||||
101495_at | CD81 | CD81 antigen | 8639 | 20584 | 2.4 | 5250 | 7579 | 1.4 | 5062 | 8355 | 1.7 | ||||||
98092_at | Plac8 | Placenta-specific 8 | 56686 | 134293 | 2.4 | 37938 | 75591 | 2.0 | 29999 | 77352 | 2.6 | ||||||
98417_at | Mx1 | Myxovirus (influenza virus) resistance 1 | 260 | 608 | 2.3 | 190 | 309 | 1.6 | 104 | 206 | 2.0 | ||||||
103459_at | Slc39a6 | Solute carrier family 39 (metal ion transporter) | 862 | 2007 | 2.3 | 1337 | 2067 | 1.5 | 971 | 1825 | 1.9 | ||||||
95358_at | Pip5k2a | Phosphatidylinositol-4-phosphate 5-kinase | 4119 | 9541 | 2.3 | 2763 | 5125 | 1.9 | 3479 | 6084 | 1.7 | ||||||
93084_at | Slc25a4 | Solute carrier family 25 (ademine translocator) | 4789 | 11081 | 2.3 | 3596 | 5997 | 1.7 | 6120 | 7659 | 1.3 | ||||||
102217_at | Gprk5 | G protein-coupled receptor kinase 5 | 772 | 1784 | 2.3 | 450 | 1351 | 3.0 | 601 | 668 | 1.1 |
Footnotes
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
This work was supported by research funds from the National Institutes of Health Grant AI14782. N.W.K. is a recipient of a Training Grant Postdoctoral Fellowship Award from National Institutes of Health Grant T32 AI7051.
Abbreviations used in this paper: MZ, marginal zone; B6, C57BL/6; FO, follicular; S1P1, 3, or 4, sphingosine-1-phosphate receptor type 1, 3, or 4; RGS, regulator of G protein; Tg, transgenic.